Landscape of warfarin and clopidogrel pharmacogenetic variants in Qatari population from whole exome datasets

Pharmacogenomics

Volumn 17, Issue 17, 2016, Pages 1891-1901

  Sivadas, Ambily ^a,b   Sharma, Parul ^c   Scaria, Vinod ^a,b,c  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

^c INDRAPRASTHA INSTITUTE OF INFORMATION TECHNOLOGY   (India)

Author keywords

Arab; clopidogrel; pharmacogenetics; Qatar; warfarin; whole exome

Indexed keywords

CLOPIDOGREL; WARFARIN;

ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DATA MINING; ETHNIC DIFFERENCE; EXOME; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; PHARMACOGENETICS; POPULATION STRUCTURE; QATARI; SEQUENCE ANALYSIS; WHOLE EXOME SEQUENCING;

EID: 84995389875     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs-2016-0130     Document Type: Article

References (61)

1. Daly AK. Genome-wide association studies in pharmacogenomics. Nat. Rev. Genet. 11(4), 241-246 (2010).
2. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N. Engl. J. Med. 364(12), 1144-1153 (2011).
3. Carr DF, Alfirevic A, Pirmohamed M. Pharmacogenomics: current state-of-the-art. Genes (Basel) 5(2), 430-443 (2014).
4. Scott SA. Personalizing medicine with clinical pharmacogenetics. Genet. Med. 13(12), 987-995 (2011).
5. Whirl-Carrillo M, McDonagh EM, Hebert JM et al. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 92(4), 414-417 (2012).
6. Ramos E, Doumatey A, Elkahloun AG et al. Pharmacogenomics, ancestry and clinical decision making for global populations. Pharmacogenomics J. 14(3), 217-222 (2014).
7. Rahemtulla T, Bhopal R. Pharmacogenetics and ethnically targeted therapies. BMJ 330(7499), 1036-1037 (2005).
8. Nebert DW, Menon AG. Pharmacogenomics, ethnicity, and susceptibility genes. Pharmacogenomics J. 1(1), 19-22 (2001).
9. Limdi NA, Brown TM, Yan Q et al. Race influences warfarin dose changes associated with genetic factors. Blood 126(4), 539-545 (2015).
10. Ortega V, Meyers D. Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine. J. Allergy Clin. Immunol. 133(1), 16-26 (2014).
11. Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc. Med. 25(1), 33-41 (2015).
12. Mallouk N, Labruyère C, Reny J-L et al. Prevalence of poor biological response to clopidogrel: a systematic review. Thromb. Haemost. 107(3), 494-506 (2012).
13. Gage BF, Eby C, Johnson JA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326-331 (2008).
14. Shuldiner AR, O'Connell JR, Bliden KP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8), 849-857 (2009).
15. Takeuchi F, McGinnis R, Bourgeois S et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5(3), e1000433 (2009).
16. Mega JL, Close SL, Wiviott SD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4), 354-362 (2009).
17. Johnson JA, Gong L, Whirl-Carrillo M et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90(4), 625-629 (2011).
18. Scott SA, Sangkuhl K, Stein CM et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharmacol. Ther. 94(3), 317-323 (2013).
19. Londin ER, Clark P, Sponziello M, Kricka LJ, Fortina P, Park JY. Performance of exome sequencing for pharmacogenomics. Per. Med. 12(2), 109-115 (2014).
20. Sivadas A, Salleh MZ, Teh LK, Scaria V. Genetic epidemiology of pharmacogenetic variants in south east Asian Malays using whole-genome sequences. Pharmacogenomics J. doi:10. 1038/tpj. 2016. 39 (2016) (Epub ahead of print).
21. Giri AK, Khan NM, Grover S et al. Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population. Pharmacogenomics 15(10), 1337-1354 (2014).
22. Giri AK, Khan NM, Basu A, Tandon N, Scaria V, Bharadwaj D. Pharmacogenetic landscape of clopidogrel in north Indians suggest distinct interpopulation differences in allele frequencies. Pharmacogenomics 15(5), 643-653 (2014).
23. Hunter-Zinck H, Musharoff S, Salit J et al. Population genetic structure of the people of Qatar. Am. J. Hum. Genet. 87(1), 17-25 (2010).
24. Alsmadi O, Thareja G, Alkayal F et al. Genetic substructure of Kuwaiti population reveals migration history. PLoS ONE 8(9), e74913 (2013).
25. Tanira MO, Al-Mukhaini MK, Al-Hinai AT, Al Balushi KA, Ahmed IS. Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose. Community Genet. 10(1), 32-37 (2007).
26. Alzahrani AM, Ragia G, Hanieh H, Manolopoulos VG. Genotyping of CYP2C9 and VKORC1 in the Arabic population of Al-Ahsa, Saudi Arabia. Biomed. Res. Int. 2013, 315980 (2013).
27. Mirghani RA, Chowdhary G, Elghazali G. Distribution of the major cytochrome P450 (CYP) 2C9 genetic variants in a Saudi population. Basic Clin. Pharmacol. Toxicol. 109(2), 111-114 (2011).
28. Saour JN, Shereen AW, Saour BJ, Mammo LA. CYP2C9 polymorphism studies in the Saudi population. Saudi Med. J. 32(4), 347-352 (2011).
29. Bu R, Gutiérrez MI, Al-Rasheed M, Belgaumi A, Bhatia K. Variable drug metabolism genes in Arab population. Pharmacogenomics J. 4(4), 260-266 (2004).
30. Risk NM. The genetic association of CYP2C19 allele with clopidogrel treatment in myocardial infarction. Qatar Found. Annu. Res. Forum Proc. 2010, BMP23 (2010).
31. Rodriguez-Flores JL, Fakhro K, Hackett NR et al. Exome sequencing identifies potential risk variants for Mendelian disorders at high prevalence in Qatar. Hum. Mutat. 35(1), 105-116 (2014).
32. Cornell University. http://mezeylab. cb. bscb. cornell. edu/Software. aspx
33. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38(16), e164 (2010).
34. Danecek P, Auton A, Abecasis G et al. The variant call format and VCF tools. Bioinformatics 27(15), 2156-2158 (2011).
35. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 31(13), 3812-3814 (2003).
36. Adzhubei IA, Schmidt S, Peshkin L et al. A method and server for predicting damaging missense mutations. Nat. Methods. 7(4), 248-249 (2010).
37. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 46(3), 310-315 (2014).
38. Li JZ, Absher DM, Tang H et al. Worldwide human relationships inferred from genome-wide patterns of variation. Science 319(5866), 1100-1104 (2008).
39. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7 (2015).
40. PLINK 1. 90 beta. www. cog-genomics. org/plink2
41. Adler D, Murdoch D. rgl: 3D visualization device system (OpenGL). R Packag. version 0. 92. (2012). https://cran. r-project. org/
42. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria (2012). https://cran. r-project. org/
43. Auton A, Abecasis GR, Altshuler DM et al. A global reference for human genetic variation. Nature 526(7571), 68-74 (2015).
44. Ross KA, Bigham AW, Edwards M, Gozdzik A, Suarez-Kurtz G, Parra EJ. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J. Hum. Genet. 55(9), 582-589 (2010).
45. Goldstein JA, Ishizaki T, Chiba K et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7(1), 59-64 (1997).
46. Desta Z, Zhao X, Shin J-G, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41(12), 913-958 (2002).
47. Sun X, Yu W-Y, Ma W-L, Huang L-H, Yang G-P. Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: a systematic review and meta-analysis. Biomed. Rep. 4(4), 498-506 (2016).
48. Caldwell MD, Awad T, Johnson JA et al. CYP4F2 genetic variant alters required warfarin dose. Blood 111(8), 4106-4112 (2008).
49. Cha P-C, Mushiroda T, Takahashi A et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum. Mol. Genet. 19(23), 4735-4744 (2010).
50. Krishna Kumar D, Shewade DG, Loriot M-A et al. Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in south Indian population. Eur. J. Clin. Pharmacol. 70(1), 47-56 (2014).
51. Shahin MHA, Khalifa SI, Gong Y et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet. Genomics 21(3), 130-135 (2011).
52. Pathare A, Al Khabori M, Alkindi S et al. Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients. J. Hum. Genet. 57(10), 665-669 (2012).
53. Pathare AV, Al Zadjali S, Misquith R et al. Warfarin pharmacogenetics: polymorphisms of the CYP2C9, CYP4F2, and VKORC1 loci in a genetically admixed Omani population. Hum. Biol. 84(1), 67-77 (2012).
54. Hicks JK, Stowe D, Willner MA et al. Implementation of clinical pharmacogenomics within a large health system: from electronic health record decision support to consultation services. Pharmacotherapy 36(8), 940-948 (2016).
55. Nutescu EA, Drozda K, Bress AP et al. Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy 33(11), 1156-1164 (2013).
56. Goldspiel BR, Flegel WA, DiPatrizio G et al. Integrating pharmacogenetic information and clinical decision support into the electronic health record. J. Am. Med. Inform. Assoc. 21(3), 522-528 (2014).
57. O'Donnell PH, Bush A, Spitz J et al. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin. Pharmacol. Ther. 92(4), 446-449 (2012).
58. Owusu-Obeng A, Weitzel KW, Hatton RC et al. Emerging roles for pharmacists in clinical implementation of pharmacogenomics. Pharmacother. J. Hum. Pharmacol. Drug Ther. 34(10), 1102-1112 (2014).
59. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ, American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th Edition: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(Suppl. 2), S7-S47 (2012).
60. Tang T, Liu J, Zuo K et al. Genotype-guided dosing of coumarin anticoagulants: a meta-analysis of randomized controlled trials. J. Cardiovasc. Pharmacol. Ther. 20(4), 387-394 (2015).
61. Elewa H, Alkhiyami D, Alsahan D, Abdel-Aziz A. A survey on the awareness and attitude of pharmacists and doctors towards the application of pharmacogenomics and its challenges in Qatar. J. Eval. Clin. Pract. 21(4), 703-709 (2015).